

## DAFTAR PUSTAKA

1. Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. *J Clin Med*. 2022 Mar 1;11(6).
2. Bertorini TE. *Neuromuscular disorders treatment and management*. 2nd ed. Missouri: Elsevier; 2022. p. 446-450.
3. Kaminski HJ, Kusner LL. *Myasthenia gravis and related disorders*. 3rd ed. Washington DC: Humana Press; 2018. p. 307-316.
4. Adams AC. *Mayo clinic essential neurology*. 2nd ed. New York: Mayo Clinic Scientific Press; 2018. p. 227-232.
5. Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. *J Med Life*. 2021 Jan 1;14(1):7–16.
6. MGFA (2022). What is myasthenia gravis?. Myasthenia Gravis Foundation of America. Available from: <https://myasthenia.org/MG-Education/What-is-Myasthenia-Gravis>. – Diakses September 2022.
7. Muhammad F, Syafrita Y, Susanti L. gambaran kualitas hidup pasien miastenia gravis di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2019;8(1).
8. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations. *J Clin Med*. 2021 Jun 1;10(11).
9. Chen J, Tian DC, Zhang C, Li Z, Zhai Y, Xiu Y, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. *The Lancet Regional Health-Western Pacific*. 2020 Nov 16;5:63.
10. Zhao S, Zhou Y, Sun W, Li Z, Wang C. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis. *Clin Exp Immunol*. 2023 Feb 1;211(2):85–92.
11. MGFA (2022). Treatment strategy. Myasthenia Gravis Foundation of America. Available from: <https://myasthenia.org/Newly-Diagnosed/Treatment-Strategy>. – Diakses Januari 2024.
12. Bauer PR, Ostermann M, Russell L, Robba C, David S, Ferreyro BL, et al. Plasma exchange in the intensive care unit: a narrative review. *Intensive Care Med*. 2022 Oct 1;48(10):1382–96.
13. Jacob S, Mazibrada G, Irani SR, Jacob A, Yudina A. The role of plasma exchange in the treatment of refractory autoimmune neurological diseases: a narrative review. *Journal of Neuroimmune Pharmacology*. 2021 Dec 1;16(4):806–17.
14. Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. *J Neurol Sci*. 2020 Mar 15;410.
15. Brust JCM (John CM). *Current diagnosis & treatment Neurology*. 3rd ed. New York: McGraw-Hill Education; 2019. p. 363-371.
16. Dogra A, Rana K, Rathod C, Prakash S. Outcome of therapeutic plasma exchange in Myasthenia gravis patients. *J Family Med Prim Care*. 2020 Dec 31;9(9):1–5.

17. Arora N, Govindarajan R, Kataria Premkumar S, Chandrasekaran N. Neuromuscular urgencies and emergencies. Switzerland: Springer; 2020. p. 105-117.
18. Ropper AH, Samuels MA, Klein JP, Prasad S. Adams and Victor's principles of neurology. 11th ed. New York: McGraw-Hill Education; 2019. p. 1469-1482.
19. Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ. Bradley and Darrof's neurology in clinical practice. 8th ed. New York: Elsevier; 2022. p. 1958-1971.
20. Permata Sari D, Nandar Kurniawan S. Myasthenia Gravis. JPHV. 2023 Mar 21;4:16–9.
21. Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021 Dec 1;19(1).
22. Mevius A, Jöres L, Biskup J, Heidebrede T, Mahic M, Wilke T, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscular Disorders. 2023 Apr 1;33(4):324–33.
23. Antonini G, Habetswallner F, Inghilleri M, Mantegazza R, Rodolico C, Saccà F, et al. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. 2023 Jun 1;9(6).
24. Misra UK, Kalita J, Singh VK, Kumar S. A study of comorbidities in myasthenia gravis. Acta Neurol Belg. 2020 Feb 1;120(1):59–64.
25. Sherwood L. Human physiology from cells to systems. 9th ed. USA: Cengage Learning; 2016. p. 244-248.
26. Greenberg DA, Simon RP, Aminoff MJ (Michael J). Clinical neurology. 10th ed. New York: McGraw-Hill Education; 2018. p. 259-262.
27. Zhao R, Luo S, Zhao C. The role of innate immunity in myasthenia gravis. Autoimmun Rev. 2021 May 1;20(5).
28. Burden SJ, Yumoto N, Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol. 2013;5(5).
29. Sansoni J, Menon N, Viali L, White S, Vucic S. Clinical features, treatments, their impact, and quality of life for Myasthenia Gravis patients in Australia. Journal of Clinical Neuroscience. 2023 Sep 28;118:16–22.
30. Tarulli A. Neurology, a clinician's approach. 3rd ed. Switzerland: Springer; 2021. p. 176-177.
31. Rosenberg RN. Atlas of clinical neurology. 4th ed. Switzerland: Springer; 2019. p. 573-581.
32. Waxman SG. Clinical neuroanatomy. 29th ed. New York: McGraw-Hill Education; 2020. p. 50-52.
33. Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring clinical treatment response in myasthenia gravis. Neurol Clin. 2018 May 1;36(2):339–53.

34. Aggelina A, Karampli E, Mavrovounis G, Boutsikos I, Pantazopoulos I, Kakavas S, et al. Evaluation of the quality of life of patients with myasthenia gravis in greece. *J Pers Med*. 2023 Jul 1;13(7).
35. Foettinger F, Pilz G, Wipfler P, Harrer A, Kern JM, Trinkla E, et al. Immunomodulatory aspects of therapeutic plasma exchange in neurological disorders—a pilot study. *Int J Mol Sci*. 2023 Apr 1;24(7):6552.
36. Apriansyah Haris Putra D, Sirin Rifdah S L, Mega Asri D P, Mahfuzzahroni M. Manajemen perawatan neurointensif pada miastenia gravis. *Jurnal Syntax Fusion*. 2021 Dec 24;1(12):1002–1010.
37. Totzeck A, Jahn M, Stolte B, Thimm A, Kleinschnitz C, Hagenacker T. Total plasma exchange in neuromuscular junction disorders—a single-center, retrospective analysis of the efficacy, safety and potential diagnostic properties in doubtful diagnosis. *J Clin Med*. 2022 Aug 1;11(15):4383.
38. Nieto-Aristizábal I, Vivas ÁJ, Ruiz-Montaña P, Aragón CC, Posso-Osorio I, Quiñones J, et al. Therapeutic plasma exchange as a treatment for autoimmune neurological disease. *Autoimmune Dis*. 2020 Jul 31;2020.
39. Ring A, Sieber WA, Studt JD, Schuepbach RA, Ganter CC, Manz MG, et al. Indications and outcomes of patients receiving therapeutic plasma exchange under critical care conditions: a retrospective eleven-year single-center study at a tertiary care center. *J Clin Med*. 2023 Apr 1;12(8):2876.
40. Altobelli C, Anastasio P, Cerrone A, Signoriello E, Lus G, Pluvio C, et al. Therapeutic plasmapheresis: a revision of literature. *Kidney Blood Press Res*. 2023;48(1):66–78.
41. Ipe TS, Davis AR, Raval JS. Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence. *Front Neurol*. 2021 Aug 31;12.
42. Liu C, Liu P, Ma M, Yang H, Qi G. Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis. *Medicine (United States)*. 2021 Apr 30;100(17):25622.
43. Reis TA, Cataneo DC, Cataneo AJM. Clinical usefulness of prethymectomy plasmapheresis in patients with myasthenia gravis: A systematic review and meta-analysis. *Interact Cardiovasc Thorac Surg*. 2019 Dec 1;29(6):867–75.
44. Raja SM, Howard JF, Juel VC, Massey JM, Chopra M, Guptill JT. Clinical outcome measures following plasma exchange for MG exacerbation. *Ann Clin Transl Neurol*. 2019 Oct 1;6(10):2114–9.
45. Al-Ahmer I, Elshony H. Determinants of quality of life changes with plasmapheresis in patients with myasthenia gravis. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*. 2021 Dec 1;57(1).
46. Tonev D, Georgieva R, Vavrek E. Our clinical experience in the treatment of myasthenia gravis acute exacerbations with a novel nanomembrane-based therapeutic plasma exchange technology. *J Clin Med*. 2022 Jul 1;11(14).

47. Lin Y, Oji S, Miyamoto K, Narita T, Kameyama M, Matsuo H. Real-world application of plasmapheresis for neurological disease: results from the japan plasmapheresis outcome and practice patterns study. *Therapeutic Apheresis and Dialysis*. 2023 Feb 1;27(1):123–35.
48. Klingele M, Allmendinger C, Thieme S, Baerens L, Fliser D, Jan B. Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness. *Sci Rep*. 2020 Dec 1;10(1).
49. Tonev DG, Momchilova AB. Therapeutic plasma exchange in certain immune-mediated neurological disorders: focus on a novel nanomembrane-based technology. *Biomedicines*. 2023 Jan 25;11(2):328.

